2024 Volume 88 Issue 2 Pages 261-
To the Editor:
Hanada et al conducted a comprehensive investigation that elucidated several clinical parameters linked to the occurrence of ventricular tachycardia/fibrillation (VT/VF) after acute myocardial infarction (AMI).1 Their study showed no significant correlation between VT/VF and mid-term clinical outcomes.
Current guidelines advocate implantable cardioverter-defibrillator (ICD) treatment predicated on left ventricular ejection fraction values. Over the 20-year study duration, the indications for ICD may have evolved with the changing clinical landscape, thereby potentially influencing the prognostic implications of VT/VF.
Over the past 2 decades, pharmacological management of heart failure has undergone a profound transformation. An array of anti-heart failure agents has been introduced, facilitating reverse remodeling and serving as prophylactic measures against arrhythmogenesis. The prevalence of these therapeutic modalities may also affect the prognostic landscape of VT/VF.
In their investigation, extracorporeal membrane oxygenation or intra-aortic balloon pumping was used as mechanical circulatory support.1 In the contemporary medical milieu, the preferred choice for cardiogenic shock resulting from AMI is a percutaneous left ventricular assist device, such as Impella, which offers robust cardiac unloading, thereby minimizing cardiac injury.2 Catheter ablation for VT/VF electrical storm has demonstrated success when performed concomitantly with Impella support.3 Consequently, if we exclusively consider recent clinical data, the prognostic implications of VT/VF may be less ominous.
None.